-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the COVID-19 pandemic is creating a pharmaceutical giant worth 100 billion U.
S.
dollars
.
SVB Leerink analyst Geoffrey Porges predicted in a report to customers on Monday that Pfizer's revenue in 2022 is expected to reach 101.
This level of income is unheard of in the pharmaceutical industry
.
Johnson & Johnson's revenue in 2020 reached 82.
Pfizer’s third-quarter revenue was US$24.
1 billion, exceeding market expectations
.
Pfizer, whose revenue has been greatly reduced due to the divestiture of generic drugs and other businesses, seems to have achieved a transformation and is now on the verge of returning to the top of the global pharmaceutical companies list
With positive and positive test data, Pfizer is seeking emergency use authorization of the drug from the US FDA
.
Prior to this, the U.
Currently, the company has signed a licensing agreement with pharmaceutical patents, allowing 95 low- and middle-income countries to produce their own versions of Paxlovid
.
In Pfizer's main target market, Porges expects that the government will want to purchase enough inventory to cover 10% to 20% of its population.
Merck also launched its own oral antiviral drug for new coronary pneumonia, molnupiravir in cooperation with Ridgeback Therapeutics
.
In clinical trials, molnupiravir reduced the risk of hospitalization or death by approximately 50%
Although Paxlovid has shown better efficacy data, Poges conservatively predicts that 50% of government contracts will be allocated to Pfizer's drug, and after obtaining full US FDA approval, the drug is expected to occupy 70% of the commercial market
.
Porges said that overall, in the four years before 2024, Paxlovid alone can bring Pfizer's cumulative sales of $67.
The new crown pneumonia vaccine and treatment drugs increase Pfizer's income, while also bringing a large amount of cash to Pfizer's balance sheet
.
Porges estimates that Pfizer’s total cash and marketable securities will increase from US$29.
Original English: https:// href="https://" target="_blank">https://
